Summary
ABSTRACT We will address a critical problem in clinical oncology, namely how highly heterogeneous, drug resistant tumor cell populations develop, and how they can be targeted. Most tumors develop resistance to almost every type of therapy, including targeted-, radiation-, chemo- or immunotherapy, ultimately leading to cancer deaths. It is essential to develop novel methods to understand the processes leading to drug resistance under complex in vivo conditions where stromal and immune elements interact with malignant cells. We will study squamous cell carcinomas (SCCs), a major contributor to h
